胃癌的分子分型研究进展

doi:10.3760/cma.j.issn.1673422X.2017.03.017

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (3): 224-227.doi: 10.3760/cma.j.issn.1673422X.2017.03.017

胃癌的分子分型研究进展

王炳智,薛丽燕,吕宁

100021 国家癌症中心 /中国医学科学院北京协和医学院肿瘤医院病理科住院医师规范化培训基地

出版日期:2017-03-08 发布日期:2017-02-28
通讯作者: 吕宁 E-mail: nlu03@126.com
基金资助:
国家自然科学基金（81402463）；北京希望马拉松专项基金（LC2015A03

）

Molecular classification of gastric cancer

Wang Bingzhi, Xue Liyan, Lyu Ning

Department of Pathology and Resident Training Base, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Online:2017-03-08 Published:2017-02-28
Contact: Lyu Ning E-mail: nlu03@126.com
Supported by:
National Natural Science Foundation

of China (81402463); Beijing Marathon of Hope Foundation (LC2015A03)

摘要/Abstract

摘要： 胃癌具有高度异质性，传统的组织病理学分型对临床工作的指导意义十分有限。随着分子检测技术的飞速发展，以各种分子为依据进行的分型能够对胃癌的临床治疗与预后提供更精准的帮助。胃癌分子分型包括Tan分型、Lei分型、克隆性分型、癌症基因组图集(TCGA)分型和亚洲癌症研究组织（ACRG）分型等，这些分型各具特色，各有优劣。

关键词: 胃肿瘤, 分子分型

Abstract: Gastric cancer has high heterogeneity, and the traditional histopathologic classification has a limited significance for clinical work. Along with the dramatic development of molecular detection technology, it may be much more helpful for the treatment and prognosis to use the molecular classifications. Recently, there have been many researches on the molecular classification of gastric cancer, such as Tan type, Lei type, clonality type, The Cancer Genome Atlas (TCGA) type, Asian Cancer Research Group (ACRG) type, and so on. All of these molecular classification methods have respective advantages and disadvantages.

Key words: Stomach neoplasms, Molecular classification

王炳智,薛丽燕,吕宁. 胃癌的分子分型研究进展[J]. 国际肿瘤学杂志, 2017, 44(3): 224-227.

Wang Bingzhi, Xue Liyan, Lyu Ning. Molecular classification of gastric cancer[J]. Journal of International Oncology, 2017, 44(3): 224-227.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J ］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update［J］. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27. DOI: 10.1158/10559965.EPI150578. ［3］ Shen J, Wei J, Wang H, et al. A threegene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer［J］. J Transl Med, 2013, 11: 73. DOI: 10.1186/147958761173. ［4］ Jeong SH, Han JH, Kim JH, et al. Bax predicts outcome in gastric cancer patients treated with 5fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy［J］. Dig Dis Sci, 2011, 56(1): 131-138. DOI: 10.1007/s1062001012808. ［5］ Qiu M, Zhou Y, Zhang X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients［J］. BMC Cancer, 2014, 14: 823. DOI: 10.1186/1471240714823. ［6］ Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric can cer, based on gene expression pattern, predict survival and respond differently to chemotherapy［J］. Gastroenterology, 2011, 141(2): 476-485, 485.e111. DOI: 10.1053/j.gastro.2011.04.042. ［7］ Lee HJ, Nam KT, Park HS, et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer［J］. Gastroenterology, 2010, 139(1): 213-225.e3. DOI: 10.1053/j.gastro.2010.04.008. ［8］ Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin17 on lymph node micrometastasis in pN0 gastric cancer［J］. Ann Surg Oncol, 2012, 19(5): 1529-1534. DOI: 10.1245/s1043401121153. ［9］ Wang J, Kang WM, Yu JC, et al. Cadherin17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway［J］. Cancer Biol Ther, 2013, 14(3): 262270. DOI: 10.4161/cbt.23299. ［10］ Choong ML, Tan SH, Tan TZ, et al. Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters ［J］. PLoS One, 2014, 9(10): e111146. DOI: 10.1371/journal.pone.0111146. ［11］ Chen K, Yang D, Li X, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy［J］. Proc Natl Acad Sci USA, 2015, 112(4): 1107-1112. DOI: 10.1073/pnas.1422640112. ［12］ Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3kinase inhibitors and 5fluorouracil［J］. Gastroenterology, 2013, 145(3): 554-565. DOI: 10.1053/j.gastro.2013.05.010. ［13］ Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma［J］. Nature, 2014, 513(7517): 202-209. DOI: 10.1038/nature13480. ［14］ Lee J, Van Hummelen P, Go C, et al. Highthroughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma［J］. PLoS One, 2012, 7(6): e38892. DOI: 10.1371/journal.pone.0038892. ［15］ Sukawa Y, Yamamoto H, Nosho K, et al. Alterations in the human epidermal growth factor receptor 2phosphatidylinositol 3kinasevAkt pathway in gastric cancer［J］. World J Gastroenterol, 2012, 18(45): 6577- 6586. DOI: 10.3748/wjg.v18.i45.6577. ［16］ Sawada T, Yashiro M, Sentani K, et al. New molecular staging with G factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis GProject committee［J］. Gastric Cancer, 2015, 18(1): 119 -128. DOI: 10.1007/s1012001403382 ［17］ Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes［J］. Nat Med, 2015, 21(5): 449-456. DOI: 10.1038/nm.3850 ［18］ Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer［J］. Nat Genet, 2011, 43(12): 1219-1223. DOI: 10.1038/ng.982 ［19］ Li Y, Li A, Glas M, et al. cMet signaling induces a reprogramming network and supports the glioblastoma stemlike phenotype［J］. Proc Natl Acad Sci USA, 2011, 108(24): 99519956. DOI: 10.1073/pnas.1016912108. ［20］ Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer［J］. Oncogene, 2010, 29(34): 4741-4751. DOI: 10.1038/onc.2010.215. ［21］ Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer［J］. BMC Med Genomics, 2011, 4: 9. DOI: 10.1186/1755879449. ［22］ Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability［J］. Gastroenterology, 2010, 138(4): 1406-1417. DOI: 10.1053/j.gastro.2009.12.010. ［23］ Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelialtomesenchymal transition［J］. Int J Cancer, 2014, 134 (3): 552-562. DOI: 10.1002/ijc.28387. ［24］ Cho JY, Lim JY, Cheong JH, et al. Gene expression signaturebased prognostic risk score in gastric cancer［J］. Clin Cancer Res, 2011, 17(7): 1850-1857. DOI: 10.1158/10780432.CCR102180. ［25］ Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets［J］. Gut, 2012, 61(5): 673-684. DOI: 10.1136/gutjnl2011301839. ［26］ Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis［J］. Lancet Oncol, 2010, 11(2): 136-146. DOI: 10.1016/S14702045(09)703432.

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[10]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[11]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[12]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[13]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[14]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[15]	李立立, 安有志, 王艳军. 替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.

胃癌的分子分型研究进展

Molecular classification of gastric cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价